Top

Published in:

01-10-2017 | Review

Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers

Authors: Nosheen Masood, Azra Yasmin

Published in: Pathology & Oncology Research | Issue 4/2017

Abstract

Involvement of micro RNAs (miRNA) is currently the focus for cancer studies as they effect the post transcriptional expression of different genes. Let-7 family is among the firstly discovered miRNAs that play important role in cell proliferation and dysregulation leading to cell based diseases including cancer. Another family, miRNA-200 prevents transformation of cell to malignant form and tumor formation by interacting with epidermal mesenchymal transition (EMT). Similarly miRNA-125 controls apoptosis and proliferation by affecting multiple genes involved in transcription, immunological defense, resistance against viral and bacterial infections that ultimately leads to cell proliferation, metastasis and finally cancer. All of these micro RNAs are known to be either upregulated or downregulated in various cancers. Current review is focused to elaborate the role of these three families of micro RNAs on different genes that ultimately cause cancer. In conclusion we can say that the miRNAs discussed here are mostly downregulated in various cancers with some exceptions when upregulation of miRNA-125 may be attributed to cancer formation.

Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854CrossRefPubMed

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. doi:10.1038/nrc1997 CrossRefPubMed

Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706. doi:10.1016/j.cell.2009.10.014 CrossRefPubMedPubMedCentral

Lee YS, Dutta A (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21(9):1025–1030. doi:10.1101/gad.1540407 CrossRefPubMedPubMedCentral

Lee H, Han S, Kwon CS, Lee D (2016) Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein & cell 7(2):100–113. doi:10.1007/s13238-015-0212-y CrossRef

Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 105(10):3903–3908. doi:10.1073/pnas.0712321105 CrossRefPubMedPubMedCentral

Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sultmann H, Lyko F (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67(4):1419–1423. doi:10.1158/0008-5472.CAN-06-4074 CrossRefPubMed

Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME (2007) Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 104(27):11400–11405. doi:10.1073/pnas.0704372104 CrossRefPubMedPubMedCentral

Barh D, Malhotra R, Ravi B, Sindhurani P (2010) MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 17(1):70–80CrossRefPubMedPubMedCentral

10.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E (2007) Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6):1109–1123. doi:10.1016/j.cell.2007.10.054 CrossRefPubMed

11.

Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70(3):1184–1194. doi:10.1158/0008-5472.CAN-09-3068 CrossRefPubMedPubMedCentral

12.

Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D, Gregory RI (2011) Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147(5):1066–1079. doi:10.1016/j.cell.2011.10.039 CrossRefPubMedPubMedCentral

13.

Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, Liang H, Li WH, Ishwaran H, Minn AJ, Rosner MR (2011) Signalling pathway for RKIP and let-7 regulates and predicts metastatic breast cancer. EMBO J 30(21):4500–4514. doi:10.1038/emboj.2011.312 CrossRefPubMedPubMedCentral

14.

Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR (2009) Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 28(4):347–358. doi:10.1038/emboj.2008.294 CrossRefPubMedPubMedCentral

15.

Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, Sahin O (2010) miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 29(30):4297–4306. doi:10.1038/onc.2010.201 CrossRefPubMed

16.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P (2012) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69(3):723–731. doi:10.1007/s00280-011-1752-3 CrossRefPubMed

17.

Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF (2012) Expression of microRNAs in the urine of patients with bladder cancer. Clinical genitourinary cancer 10(2):106–113. doi:10.1016/j.clgc.2012.01.001 CrossRefPubMed

18.

Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Orntoft TF, Kjems J, Clark SJ (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128(6):1327–1334. doi:10.1002/ijc.25461 CrossRefPubMed

19.

Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219(2):214–221. doi:10.1002/path.2586 CrossRefPubMed

20.

Kohler CU, Bryk O, Meier S, Lang K, Rozynek P, Bruning T, Kafferlein HU (2013) Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochem Biophys Res Commun 438(1):48–53. doi:10.1016/j.bbrc.2013.07.021 CrossRefPubMed

21.

Radisky DC (2011) miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast cancer research : BCR 13(3):110. doi:10.1186/bcr2885 CrossRefPubMedPubMedCentral

22.

Teng Y, Mei Y, Hawthorn L, Cowell JK (2014) WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene 33(2):203–211. doi:10.1038/onc.2012.565 CrossRefPubMed

23.

Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y (2014) MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene 33(31):4077–4088. doi:10.1038/onc.2013.370 CrossRefPubMed

24.

Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 18(21):5972–5982. doi:10.1158/1078-0432.CCR-12-1407 CrossRef

25.

Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L, Liu W (2013) miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep 7(5):1579–1584. doi:10.3892/mmr.2013.1403 CrossRefPubMed

26.

Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW, Wang X (2010) A microRNA expression signature for cervical cancer prognosis. Cancer Res 70(4):1441–1448. doi:10.1158/0008-5472.CAN-09-3289 CrossRefPubMedPubMedCentral

27.

Pedroza-Torres A, Lopez-Urrutia E, Garcia-Castillo V, Jacobo-Herrera N, Herrera LA, Peralta-Zaragoza O, Lopez-Camarillo C, De Leon DC, Fernandez-Retana J, Cerna-Cortes JF, Perez-Plasencia C (2014) MicroRNAs in cervical cancer: evidences for a miRNA profile deregulated by HPV and its impact on radio-resistance. Molecules 19(5):6263–6281. doi:10.3390/molecules19056263 CrossRefPubMed

28.

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G, Maciejewski R (2013) Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer 132(7):1633–1645. doi:10.1002/ijc.27840 CrossRefPubMed

29.

Diaz-Martin J, Diaz-Lopez A, Moreno-Bueno G, Castilla MA, Rosa-Rosa JM, Cano A, Palacios J (2014) A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol 232(3):319–329. doi:10.1002/path.4289 CrossRefPubMed

30.

Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2014) Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 259(4):735–743. doi:10.1097/SLA.0b013e3182a6909d CrossRefPubMedPubMedCentral

31.

Tu HF, Lin SC, Chang KW (2013) MicroRNA aberrances in head and neck cancer: pathogenetic and clinical significance. Current opinion in otolaryngology & head and neck surgery 21(2):104–111. doi:10.1097/MOO.0b013e32835e1d6e CrossRef

32.

Tamagawa S, Beder LB, Hotomi M, Gunduz M, Yata K, Grenman R, Yamanaka N (2014) Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med 33(4):879–886. doi:10.3892/ijmm.2014.1625 CrossRefPubMed

33.

Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA (2011) EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71(8):3087–3097. doi:10.1158/0008-5472.CAN-10-3035 CrossRefPubMedPubMedCentral

34.

Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ, Gibbons DL (2016) The miR-200 family and the miR-183 ~ 96 ~ 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers. Oncogene 35(2):173–186. doi:10.1038/onc.2015.71 CrossRefPubMed

35.

Feng B, Wang R, Chen LB (2012) Review of miR-200b and cancer chemosensitivity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 66(6):397–402. doi:10.1016/j.biopha.2012.06.002 CrossRef

36.

Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X (2013) Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 19(5):1213–1224. doi:10.1158/1078-0432.CCR-12-2726 CrossRef

37.

Jabbari N, Reavis AN, McDonald JF (2014) Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells. Journal of ovarian research 7:12. doi:10.1186/1757-2215-7-12 CrossRefPubMedPubMedCentral

38.

Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW, Wang Y (2011) MicroRNAs associated with metastatic prostate cancer. PLoS One 6(9):e24950. doi:10.1371/journal.pone.0024950 CrossRefPubMedPubMedCentral

39.

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X (2014) miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clinical cancer research : an official journal of the American Association for Cancer Research 20(10):2617–2630. doi:10.1158/1078-0432.CCR-13-3224 CrossRef

40.

Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res 14(10A):1902–1910. doi:10.1101/gr.2722704 CrossRefPubMedPubMedCentral

41.

Jiang L, Huang Q, Chang J, Wang E, Qiu X (2011) MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res 37(7):387–398. doi:10.3109/01902148.2010.492068 CrossRefPubMed

42.

Yanokura M, Banno K, Iida M, Irie H, Umene K, Masuda K, Kobayashi Y, Tominaga E, Aoki D (2015) MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI J 14:190–198. doi:10.17179/excli2014-590 PubMedPubMedCentral

43.

Shang C, Lu YM, Meng LR (2012) MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Medical science monitor : international medical journal of experimental and clinical research 18(4):BR149–BR155CrossRef

44.

Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H, Mori M (2011) MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 38(5):1437–1443. doi:10.3892/ijo.2011.969 PubMed

45.

Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P (2009) Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 46(5):358–360. doi:10.1136/jmg.2008.063123 CrossRefPubMed

46.

Mitra S, Mukherjee N, Das S, Das P, Panda CK, Chakrabarti J (2014) Anomalous altered expressions of downstream gene-targets in TP53-miRNA pathways in head and neck cancer. Scientific reports 4:6280. doi:10.1038/srep06280 CrossRefPubMedPubMedCentral

47.

Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T, Volinia S, Croce CM (2014) Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 33(6):702–712. doi:10.1038/onc.2013.13 CrossRefPubMed

48.

Sun YM, Lin KY, Chen YQ (2013) Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 6:6. doi:10.1186/1756-8722-6-6 CrossRefPubMedPubMedCentral

49.

Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW (2013) Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One 8(4):e61064. doi:10.1371/journal.pone.0061064 CrossRefPubMedPubMedCentral

50.

Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, Wang E (2010) Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 10:318. doi:10.1186/1471-2407-10-318 CrossRefPubMedPubMedCentral

51.

Hsieh TH, Hsu CY, Tsai CF, Long CY, Wu CH, Wu DC, Lee JN, Chang WC, Tsai EM (2015) HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells. Molecular therapy : the journal of the American Society of Gene Therapy 23(4):656–666. doi:10.1038/mt.2014.247 CrossRef

52.

Gonzalez-Vallinas M, Breuhahn K (2016) MicroRNAs are key regulators of hepatocellular carcinoma (HCC) cell dissemination-what we learned from microRNA-494. Hepatobiliary surgery and nutrition 5(4):372–376. doi:10.21037/hbsn.2016.05.07 CrossRefPubMedPubMedCentral

53.

Guo X, Wu Y, Hartley RS (2009) MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol 6(5):575–583CrossRefPubMedPubMedCentral

54.

Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, Liu B (2013) Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis 4:e556. doi:10.1038/cddis.2013.79 CrossRefPubMedPubMedCentral

55.

Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, Dong W, Huang J, Lin T (2011) MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 128(8):1758–1769. doi:10.1002/ijc.25509 CrossRefPubMed

56.

Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125(2):345–352. doi:10.1002/ijc.24390 CrossRefPubMed

57.

Banzhaf-Strathmann J, Edbauer D (2014) Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell communication and signaling : CCS 12:30. doi:10.1186/1478-811X-12-30 CrossRefPubMedCentral

58.

Wang H (2016) Predicting MicroRNA biomarkers for cancer using phylogenetic tree and microarray analysis. Int J Mol Sci 17(5). doi:10.3390/ijms17050773

59.

Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H (2012) Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One 7(6):e38298. doi:10.1371/journal.pone.0038298 CrossRefPubMedPubMedCentral

60.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641–2650. doi:10.1056/NEJMoa0803785 CrossRefPubMedPubMedCentral

61.

Takebe T, Enomura M, Yoshizawa E, Kimura M, Koike H, Ueno Y, Matsuzaki T, Yamazaki T, Toyohara T, Osafune K, Nakauchi H, Yoshikawa HY, Taniguchi H (2015) Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation. Cell Stem Cell 16(5):556–565. doi:10.1016/j.stem.2015.03.004 CrossRefPubMed

62.

Feng X, Wang Z, Fillmore R, Xi Y (2014) MiR-200, a new star miRNA in human cancer. Cancer Lett 344(2):166–173. doi:10.1016/j.canlet.2013.11.004 CrossRefPubMed

Title: Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers
Authors: Nosheen Masood
Azra Yasmin
Publication date: 01-10-2017
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0184-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Seminal Tract Amyloidosis: Synchronous Amyloidosis of the Seminal Vesicles, Deferent Ducts and Ejaculatory Ducts

Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study

Inducing Polyclonal Eag1-Specific Antibodies by Vaccination with a Linear Epitope Immunogen and Its Relation to Breast Tumorigenesis

Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia

Transcriptional Regulatory Network Analysis for Gastric Cancer Based on mRNA Microarray

Unusual Signal Patterns of Break-apart FISH Probes Used in the Diagnosis of Soft Tissue Sarcomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer